Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency

Supporting evidence

• Evaluation report

• Committee papers (PDF 10.73 MB)

  Published:

  20 September 2023